312 related articles for article (PubMed ID: 33896588)
1. Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature.
Giannone G; Scotto G; Katsaros D; De Giorgi U; Farolfi A; Borella F; Cosma S; Ferrero A; Mangiacotti S; Villa M; Tuninetti V; Ghisoni E; Turinetto M; Mittica G; Gemmiti S; Zavallone L; Aglietta M; Pasini B; Di Maio M; Valabrega G
Gynecol Oncol; 2021 Jul; 162(1):80-87. PubMed ID: 33896588
[TBL] [Abstract][Full Text] [Related]
2. Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?
Tomao F; Musacchio L; Di Mauro F; Boccia SM; Di Donato V; Giancotti A; Perniola G; Palaia I; Muzii L; Benedetti Panici P
Gynecol Oncol; 2019 Jul; 154(1):138-143. PubMed ID: 31079832
[TBL] [Abstract][Full Text] [Related]
3. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
[TBL] [Abstract][Full Text] [Related]
4. BRCA Mutation Status Is Not Associated With Increased Hematologic Toxicity Among Patients Undergoing Platinum-Based Chemotherapy for Ovarian Cancer.
Kotsopoulos J; Willows K; Trat S; Kim RH; Volenik A; Sun P; Narod SA; Boyd J; May T
Int J Gynecol Cancer; 2018 Jan; 28(1):69-76. PubMed ID: 29194191
[TBL] [Abstract][Full Text] [Related]
5. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin.
Safra T; Borgato L; Nicoletto MO; Rolnitzky L; Pelles-Avraham S; Geva R; Donach ME; Curtin J; Novetsky A; Grenader T; Lai WC; Gabizon A; Boyd L; Muggia F
Mol Cancer Ther; 2011 Oct; 10(10):2000-7. PubMed ID: 21835933
[TBL] [Abstract][Full Text] [Related]
6. Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
Cecere SC; Giannone G; Salutari V; Arenare L; Lorusso D; Ronzino G; Lauria R; Cormio G; Carella C; Scollo P; Ghizzoni V; Raspagliesi F; Di Napoli M; Mazzoni E; Marchetti C; Bergamini A; Orditura M; Valabrega G; Scambia G; Maltese G; De Matteis E; Cardalesi C; Loizzi V; Boccia S; Naglieri E; Scandurra G; Pignata S
Gynecol Oncol; 2020 Jan; 156(1):38-44. PubMed ID: 31699415
[TBL] [Abstract][Full Text] [Related]
7. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21).
Artioli G; Giannone G; Valabrega G; Maggiorotto F; Genta S; Pignata S; Lorusso D; Cormio G; Scalone S; Nicoletto MO; Greco F; Rossi E; Spagnoletti I; De Giorgi U; Orditura M; Mosconi AM; Kardhashi A; Bogliolo S; Borgato L
Gynecol Oncol; 2021 Jun; 161(3):755-761. PubMed ID: 33888336
[TBL] [Abstract][Full Text] [Related]
9. Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without
Garcia A; Frahm C; Jeter JM; Abraham I; Chambers SK; Cragun JM; McBride A
J Adv Pract Oncol; 2019 Jul; 10(5):428-439. PubMed ID: 33457057
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer.
Paik ES; Heo EJ; Choi CH; Kim JH; Kim JW; Kim YM; Park SY; Lee JW; Kim JW; Kim BG
Cancer Sci; 2021 Dec; 112(12):5055-5067. PubMed ID: 34657357
[TBL] [Abstract][Full Text] [Related]
11. Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis.
Rebelatto TF; Falavigna M; Pozzari M; Spada F; Cella CA; Laffi A; Pellicori S; Fazio N
Cancer Treat Rev; 2019 Nov; 80():101895. PubMed ID: 31542591
[TBL] [Abstract][Full Text] [Related]
12. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
Yang D; Khan S; Sun Y; Hess K; Shmulevich I; Sood AK; Zhang W
JAMA; 2011 Oct; 306(14):1557-65. PubMed ID: 21990299
[TBL] [Abstract][Full Text] [Related]
13. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
14. Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status.
Stasenko M; Cybulska P; Feit N; Makker V; Konner J; O'Cearbhaill RE; Alektiar KM; Beal K; Gardner GJ; Long Roche KC; Sonoda Y; Chi DS; Zivanovic O; Leitao MM; Cadoo KA; Tew WP
Gynecol Oncol; 2019 Jul; 154(1):144-149. PubMed ID: 31113680
[TBL] [Abstract][Full Text] [Related]
15. The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis.
Sun C; Li N; Ding D; Weng D; Meng L; Chen G; Ma D
PLoS One; 2014; 9(5):e95285. PubMed ID: 24788697
[TBL] [Abstract][Full Text] [Related]
16. [Clinical significance and distribution of BRCA genes mutation in sporadic high grade serous ovarian cancer].
Liu WL; Wang ZZ; Zhao JZ; Hou YY; Wu XX; Li W; Dong B; Tong TT; Guo YJ
Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):26-31. PubMed ID: 28190312
[No Abstract] [Full Text] [Related]
17. Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity.
Gallagher DJ; Konner JA; Bell-McGuinn KM; Bhatia J; Sabbatini P; Aghajanian CA; Offit K; Barakat RR; Spriggs DR; Kauff ND
Ann Oncol; 2011 May; 22(5):1127-1132. PubMed ID: 21084428
[TBL] [Abstract][Full Text] [Related]
18. Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer.
Bookman MA; Tyczynski JE; Espirito JL; Wilson TW; Fernandes AW
Gynecol Oncol; 2017 Jul; 146(1):58-63. PubMed ID: 28454659
[TBL] [Abstract][Full Text] [Related]
19. Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.
Tomao F; Bardhi E; Di Pinto A; Sassu CM; Biagioli E; Petrella MC; Palaia I; Muzii L; Colombo N; Panici PB
Cancer Treat Rev; 2019 Nov; 80():101909. PubMed ID: 31629204
[TBL] [Abstract][Full Text] [Related]
20. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.
Vollebergh MA; Lips EH; Nederlof PM; Wessels LF; Wesseling J; Vd Vijver MJ; de Vries EG; van Tinteren H; Jonkers J; Hauptmann M; Rodenhuis S; Linn SC
Breast Cancer Res; 2014 May; 16(3):R47. PubMed ID: 24887359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
